NPPA Caps Trade Margins on 137 Anti-Cancer Drugs to Improve Affordability

Why in the News?

The National Pharmaceutical Pricing Authority (**NPPA**) has capped trade margins on the Maximum Retail Price (MRP) of **137 anti-cancer drugs** based on recommendations by an Expert Committee constituted by the Directorate General of Health Services (DGHS).

Key Features / Major Points:

- Trade Margin Rationalisation (TMR):

- Trade margins for non-scheduled anti-cancer medications have been capped at a maximum of **30%**.

- Substantial Price Reductions:

- 76 pharmaceutical companies have reported revised MRPs covering 1,225 anti-cancer formulations.

- Price reductions have been reported across 1,031 formulations, with **over 600 brands registering a price drop of more than 50%**, and the **highest reduction touching 96.45%**.

- Consumer Savings:

- The price rationalisation is estimated to result in annual savings of **₹3,502.31 crore** for consumers.

- Future-Proofing:

- Out of the 137 identified drugs, 10–15 are yet to be launched in India; however, TMR will automatically apply to them upon their launch.

---

Static GK Facts:

- National Pharmaceutical Pricing Authority (NPPA):

- Established: **August 29, 1997** | Headquarters: **New Delhi**.

- Parent Ministry: Department of Pharmaceuticals, **Ministry of Chemicals and Fertilizers**.

- Regulatory Framework:

- Implemented under the provisions of the **Drugs (Prices Control) Order, 2013 (DPCO)**.

One-Liner Quiz (All Competitive Exams):

Q: Which statutory body capped trade margins on 137 anti-cancer drugs at 30%?

A: National Pharmaceutical Pricing Authority (NPPA)

Q: What is the estimated annual consumer savings expected from the NPPA's trade margin cap on anti-cancer drugs?

A: ₹3,502.31 crore

Q: Under which Union Ministry does the NPPA operate?

A: Ministry of Chemicals and Fertilizers

#NPPA #AntiCancerDrugs #TradeMarginRationalization #Healthcare #PharmaPricing #CurrentAffairs #StaticGK